Therapeutic Advances and Challenges in the Management of HER2-Positive Gastroesophageal Cancers
Gastroesophageal cancer is one of the most common cancers in the world, with a high rate of mortality. While there has been significant progress over the past decade, particularly with the addition of anti-HER2 therapies to platinum-based chemotherapy agents in the advanced setting, the prognosis re...
Main Authors: | Jeremy Chuang, Samuel Klempner, Kevin Waters, Katelyn Atkins, Joseph Chao, May Cho, Andrew Hendifar, Alexandra Gangi, Miguel Burch, Pareen Mehta, Jun Gong |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-04-01
|
Series: | Diseases |
Subjects: | |
Online Access: | https://www.mdpi.com/2079-9721/10/2/23 |
Similar Items
-
Progress and challenges in HER2-positive gastroesophageal adenocarcinoma
by: Dan Zhao, et al.
Published: (2019-05-01) -
Dual HER2 blockade with lapatinib and trastuzumab in combination with chemotherapy in metastatic gastroesophageal adenocarcinoma
by: E. Von Cheong, et al.
Published: (2021-04-01) -
Targeted and Immunotherapy Approaches in HER2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma: A New Era
by: Maluki Radford, et al.
Published: (2023-08-01) -
Expression of Her2-Neu in Primary Gastric and Gastroesophageal Adenocarcinoma: An Experience from a Tertiary Center in South India
by: Aditi Damle, et al. -
Pertuzumab in combination with trastuzumab and chemotherapy for Chinese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subpopulation analysis of the JACOB trial
by: Tianshu Liu, et al.
Published: (2019-06-01)